Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
24.80    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.60 (2.469%)
Market Cap: £106.76m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Dividend Timetable

20 Sep 2022 07:01

RNS Number : 9264Z
EKF Diagnostics Holdings PLC
20 September 2022
Β 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Β 

Dividend Timetable

Β 

EKF Diagnostics Holdings plc (AIM: EKF), theβ€―AIM-listed global diagnostics business, confirms that, further to the passing of the resolution at the AGM, a cash dividend of 1.2p per ordinary share will be paid in relation to its 2021 results as per the below timetable. The dividend will be paid to shareholders, on the register at close of business on 4 November 2022, on 1 December 2022.

Β 

The dividend timetable dates are detailed below:

Β 

Ex-dividend date:

3 November 2022

Record date:

4 November 2022

Payment date:

1 December 2022

Β 

Β 

Β 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Mike Salter, CEO / Marc Davies, CFO

Β Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Oliver Platts

Investec Bank plc (Joint Broker)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams / Ben Farrow

Walbrook PRΒ Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

Β 

Β 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

Β 

Point-of-Care

Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.

Β 

Central Laboratory

Clinical chemistry, Small lab analysers, Centrifuges

Beta-Hydroxybutyrate (Ξ²-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin

Β 

Life Sciences

Enzyme fermentation, Custom products and Bulk fermentation

Β 

Contract Manufacturing

Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits

Β 

Laboratory Testing

Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing.Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCGPUCPBUPPGQB
Date   Source Headline
27th May 20143:59 pmRNSHolding(s) in Company
23rd May 201411:30 amRNSHolding(s) in Company
21st May 20144:40 pmRNSSecond Price Monitoring Extn
21st May 20144:35 pmRNSPrice Monitoring Extension
20th May 20144:36 pmRNSResult of AGM
20th May 20147:01 amRNSAGM Statement
20th May 20147:00 amRNSSelah to provide Women's Health testing services
19th May 20143:13 pmRNSHolding(s) in Company - Replacement
16th May 20144:35 pmRNSHolding(s) in Company
15th May 20147:00 amRNSDirector/PDMR Shareholding
8th May 20141:10 pmRNSDirector/PDMR Shareholding
7th May 20147:00 amRNSSelah update
30th Apr 20147:01 amRNSHolding(s) in Company
23rd Apr 20144:46 pmRNSHolding(s) in Company
23rd Apr 20143:33 pmRNSHolding(s) in Company
17th Apr 20141:13 pmRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSInvestor Teach-In
11th Apr 201411:33 amRNSResults of General Meeting and Total Voting Rights
10th Apr 20149:33 amRNSResult of Offer
31st Mar 20144:46 pmRNSDirector Resignation
31st Mar 201410:01 amRNSHolding(s) in Company
26th Mar 20144:18 pmRNSHolding(s) in Company
24th Mar 20147:00 amRNSHolding(s) in Company Replacement
20th Mar 201411:26 amRNSResult of the Placing
20th Mar 20147:00 amRNSProposed Acquisitions, Placing & Offer
12th Mar 20147:00 amRNSAcquisition of Separation Technology, Inc.
4th Mar 201411:16 amRNSTransfer of production
26th Feb 20147:00 amRNSFinal Results
18th Feb 20147:00 amRNSQuo-Lab registration in Mexico
17th Feb 20147:00 amRNSNotice of Results
28th Jan 201412:21 pmRNSAdditional Listing
27th Jan 20147:00 amRNSYear end trading update
24th Jan 20147:00 amRNSHolding(s) in Company
20th Jan 20147:00 amRNSPointMan enriches low-level mutations from blood
19th Nov 20137:00 amRNSAcute Kidney Injury marker development
4th Nov 20137:00 amRNSNew PointManT DNA enrichment products launched
30th Oct 20133:10 pmRNSHolding(s) in Company
8th Oct 20138:25 amRNSHolding(s) in Company
3rd Oct 20139:03 amRNSChange of Registered Office
25th Sep 201311:34 amRNSHolding(s) in Company
19th Sep 20137:28 amRNSInvestor Results Briefing
16th Sep 20137:00 amRNSInterim Results
14th Aug 20137:00 amRNSInvestor Teach-In
1st Aug 20137:00 amRNSTrading update
25th Jul 20137:00 amRNSInvestor Teach-In
23rd Jul 20137:00 amRNSSenior management update
4th Jul 201312:09 pmRNSHolding(s) in Company
26th Jun 20135:43 pmRNSAnalyst & Investor Teach-In
18th Jun 201310:17 amRNSDirector Share Transfer
11th Jun 20133:52 pmRNSAmendment to Long-Term Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.